Modern Slavery and Human Rights Statement

Arva AI is committed to conducting business ethically and with integrity. We have a zero-tolerance approach to modern slavery and human trafficking and are committed to preventing such practices in our operations and supply chains.

Our Business

Arva AI is a technology company providing AI-driven solutions to financial institutions. Our operations are primarily digital, with a limited physical supply chain.

Our Commitment

We are committed to upholding fundamental human rights and ensuring that modern slavery does not take place in any part of our business or supply chain. This includes:

• Prohibiting forced or compulsory labour

• Prohibiting human trafficking

• Prohibiting child labour and exploitation

• Promoting fair and safe working conditions

Risk and Approach

Given the nature of our business, we consider the risk of modern slavery within our direct operations to be low.

However, we recognise potential risks may arise through third-party suppliers and service providers. We take a proportionate, risk-based approach to identifying and mitigating these risks.

Due Diligence

We take steps to ensure our suppliers and partners align with our values, including:

• Working with reputable vendors and service providers

• Conducting appropriate due diligence where necessary

• Avoiding engagement with organisations where there are known or suspected human rights concerns

Policies and Governance

Our commitment to ethical business practices is supported by internal policies, including:

• Anti-Bribery & Corruption Policy

• Financial Crime Policy

Responsibility for oversight of these matters sits with senior management.

Reporting Concerns

We encourage employees, partners, and third parties to report any concerns related to modern slavery or human rights abuses.

Concerns can be raised confidentially via: hello@arva.ai

We do not tolerate retaliation against individuals who raise concerns in good faith.

Approval

This statement has been approved by senior management and will be reviewed annually.